VTV Therapeutics is a clinical stage biotech company dedicated to enhancing the well-being of individuals with diabetes. With a focus on innovative technology, vTv has developed a pipeline of clinical drug candidates, spearheaded by our TTP399 program, aimed at improving the treatment of type 1 diabetes. In addition to this groundbreaking program, vTv is collaborating with development partners to explore potential treatments for type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

At vTv Therapeutics, we are driven by a commitment to improving the lives of diabetes patients. Through our scientific advancements and collaborative efforts, we are striving to make a positive impact on the lives of those affected by various medical conditions. For more information or to get in touch with us, visit our website or reach out to us on Twitter or LinkedIn.

Together, let's create a healthier future